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INTRODUCTION
Patients with chronic renal failure (CRF) show
increased serum phosphate levels due to impaired
phosphate excretion (1). Hyperphosphatemia in-
duces secondary hyperparathyroidism (2-4) and re-
nal osteodystrophy (5), which adversely affect the
patient’s prognosis and quality of life (6, 7).
Aluminum gel and calcium carbonate have been
used clinically as phosphate-binding inorganic com-
pounds for treatment of hyperphosphatemia. How-
ever, administration of aluminum gel is now prohib-
ited due to the toxicity of aluminum, which may in-
duce encephalopathy or osteopathy (8-12). On the
other hand, the use of calcium carbonate induces
hypercalcemia, which accelerates the calcification of
blood vessels (13-15). To overcome these problems,
sevelamer hydrochloride (16), which is a phosphate-
binding organic polymer, has been developed. How-
ever, this compound also frequently induces adverse
reactions, such as constipation, abdominal pain, and
abdominal fullness (17, 18). Therefore, the develop-
ment of alternative phosphate binders with fewer
side effects is required.
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In the present study, we synthesized a titanium
oxide-like compound, TAP [titanium (IV) oxide ad-
sorbing phosphate], as a candidate phosphate ad-
sorbent and evaluated its applicability for the treat-
ment of hyperphosphatemia in CRF using adenine-
induced renal failure model rats. We propose that
TAP is an alternative phosphate-binding inorganic
compound useful for prevention of hyperphos-
phatemia in CRF patients.
MATERIALS AND METHODS
Preparation of TAP
We chemically synthesized the novel titanium
oxide-like compound TAP as follows. Briefly, 171 g
of ammonium sulfate was dissolved in 400 ml of
water by agitation, and 200 g of titanium tetrachlo-
ride solution (65.4% TiCl4) was added. The solution
was heated at 100for 3 h under strongly acidic
conditions (pH1.0). The obtained sediment was re-
covered by filtration, washed with distilled water,
and dried at 60.
Reagents
Sevelamer hydrochloride (Renagel) was pur-
chased from Chugai Pharmaceutical, Co., Ltd, Japan.
Calcium carbonate used in this study was Japanese
pharmacopoeia grade.
Phosphate adsorption test in vitro
Phosphate solutions containing various concen-
trations (5, 10, 20, 40, or 60 mM) of NaH2PO4 were
used, and their pH values were adjusted using HCl
or NaOH. TAP (0.5 g) was added to 50 ml of each
phosphate solution, and the mixtures were agitated
in a water bath at 37. The mixtures were then fil-
tered with 0.2-μm nylon membranes. The phos-
phate concentrations in the flow-through fractions
were measured, and the rates of phosphate adsorp-
tion were calculated.
Analytical procedure
The concentrations of phosphate and sulfate were
measured by the ion chromatography method using
an AS4A column (DIONEX) and AMMS (anion
micro membrane suppressor) under the following
conditions. The AS4A column was injected with 25
μl of the sample and operated at a flow rate of 1.5
ml/min. Elution was performed with elution buffer
(10 mM sodium bicarbonate, 15 mM sodium car-
bonate, and AMMS) at a flow rate of 4.0 ml/min.
In chemical regeneration mode, 12.5 mM sulfuric
acid was used as a regenerant.
Phosphate adsorption test of TAP in CRF model rats
Eighteen 8-week-old male Crj : CD (SD) IGS rats
were purchased from Charles River Japan (Tokyo,
Japan). We designed minimum number of experi-
mental animal (three rats per group) due to the
capacity of our metabolic cage. Rats were housed
individually in plastic cages and acclimated for five
days before starting the experiment. Distilled water
and AIN-76 (19)-based diet were provided ad libi-
tum . The room was maintained at a temperature of
232, humidity of 5510%, and a 13-h light/11-
h dark cycle. All of the animal experiments were
performed according to the guidelines for animal ex-
periments approved by the University of Tokushima.
Adenine-induced CRF model rats were generated
by referring to the literature (20-22). Briefly, after
acclimation, the rats were divided into six groups
without deviation on the mean body weights. Four
groups were fed AIN-76 plus 0.675% adenine supple-
mented with TAP (3% or 10%), sevelamer hydrochlo-
ride (3%), or calcium carbonate (3%), respectively,
and one group was fed AIN-76 plus 0.675% adenine
alone (control group) for 31 days. The remaining
three rats were fed only AIN-76 diet throughout
the experiment (normal group). Dietary intakes of
the rats were recorded every day.
Blood analysis
Orbital blood was collected from all of the rats
on days 1, 14, 24, and 31 after administration of
the test reagents, and the serum levels of phos-
phate, calcium, blood urea nitrogen (BUN), and cre-
atinine were measured with Hitachi 7600 automatic
analyzer by employing Fiske-Subbarow method,
Arsenazo-III method, Urease-GLDH method, and
enzymatic method, respectively.
Urinalysis
At 24 and 31 days after administration of the test
reagents, the rats were settled into metabolic cages,
24-h urine was collected, and the urinary phosphate
levels were measured (Fiske-Subbarow method :
Hitachi7600 automatic analyzer).
Statistical analysis
Data are expressed as the meansstandard de-
viation. Differences between the control group and
treated groups were assessed by unpaired t -test. P
0.05 was considered to indicate significance.
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RESULTS
Properties of TAP
The chemical characteristics of TAP and a com-
parison of the X-ray diffraction patterns of TAP and
TiO2 are shown in Table 1 and Figure 1, respec-
tively. TAP is a titanium oxide-like compound con-
taining TiO2 (63.2%), SO4 (13.7%), and H2O (13.3%).
The X-ray diffraction pattern indicated that TAP is
a TiO2 with an anatase structure and extremely low
crystal formation (Figure 1).
Phosphate adsorption of TAP in vitro
The phosphate-binding capacity of TAP was as-
sessed using phosphate solutions of various con-
centrations (5, 10, 20, 40, and 60 mM NaH2PO4) at
pH1.2 and 6.8 (Table 2). As the phosphate concen-
tration increased, the amount of phosphate adsorbed
by TAP increased. On the other hand, the propor-
tion of the phosphate adsorbed by TAP decreased
to 34.8% when 60 mM phosphate solution was used,
indicating that most of the TAP in the 60 mM phos-
phate solution was saturated. There were no differ-
ences in the phosphate-binding properties of TAP
at pH1.2 and 6.8. The final pH of the mixtures de-
creased when phosphate solutions at pH6.8 were
used. We measured the sulfate concentrations in
the mixtures after addition of TAP (Figure 2). TAP
Table 1. Chemical characteristics of TAP
Subjects Analysis data
TiO2 content (%) 63.2
SO4 content (%) 13.7
Dry loss (105, 2 h) (%) 13.3
Surface area (m2/g) 165.9
Mean pore size (μm) 11.8
Apparent density (g/ml) 0.74
Fig. 1. X-ray diffraction patterns of TAP (1) and TiO2 of Japa-
nese pharmacopoeia grade (2).
Table 2. Phosphate adsorption of TAP
Condition
Phosphate concentration of solution (mM)
5 10 20 40 60
pH1.2
Adsorbed P (mg/g) 16.11 32.56 52.15 60.87 66.20
Adsorption rate a (%) 100.0 100.0 83.1 47.1 34.8
Final pH b 1.22 1.16 1.15 1.13 1.14
pH6.8
Adsorbed P (mg/g) 16.26 32.08 55.26 61.45 68.38
Adsorption rate a (%) 100.0 100.0 87.4 48.8 36.4
Final pH b 2.23 2.20 2.37 3.58 5.34
a Adsorption rate indicates the percentages of TAP-adsorbed phosphate (P) to total P content in the test solution.
b The decrease in final pH value was derived from the release of sulfate ions into the test solution due to ionic exchange between
sulfate groups of TAP and phosphate ions.
Fig. 2. Ion exchange between sulfate groups in TAP and ex-
ogenous phosphate ions. The concentration of sulfate released
from TAP in solutions of various phosphate concentrations were
measured at pH1.2 (closed circles) and 6.8 (open triangles).
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released 0.30 to 0.37 mM sulfate in the absence of
phosphate, indicating that the sulfate groups in TAP
are easily released. The released sulfate increased
in proportion to the amount of TAP-adsorbed phos-
phate and almost reached a plateau at phosphate
concentrations above 40 mM.
Phosphate adsorption rate of TAP in vitro
The phosphate adsorption rate of TAP was meas-
ured at 37in 60 mM phosphate solution adjusted
to pH1.2 or 6.8. As shown in Figure 3, at both pH
values, TAP showed rapid phosphate adsorption,
which reached a plateau after 2 h of incubation.
Effects of pH on in vitro phosphate adsorption of
TAP
The effects of pH on phosphate adsorption capa-
bility of TAP were determined using 60 mM phos-
phate solutions adjusted to various pH values (1.2,
3.0, 5.0, 6.8, 8.0, 9.0, 10.0, 11.0, or 12.0). As shown
in Figure 4, the capacity of TAP to adsorb phosphate
ranged from 66.20 to 72.77 mg/g at final pH values
ranging from 1.22 to 7.27. TAP showed stable phos-
phate adsorption under acidic to neutral conditions.
However, the phosphate adsorption of TAP was
markedly reduced at pH10.21, indicating that the
phosphate-binding of TAP is reduced under strongly
basic conditions.
Effects of TAP on serum phosphate levels in CFR
model rats
We evaluated the potential of TAP as a therapeu-
tic agent to prevent hyperphosphatemia in CRF pa-
tients using experimental CRF model rats. Adenine-
induced CRF model rats were fed a diet supple-
mented with TAP (3% or 10%), sevelamer hydrochlo-
ride (3%), or calcium carbonate (3%) for 31 days,
and the serum phosphate levels were compared.
Table 3 shows the daily dietary intake of the rats
in each experimental group during the experimen-
tal period of 31 days. The dietary intake of CRF
model rats was significantly lower than that of nor-
mal controls. Among the CRF groups, the mean die-
tary intake of the 10% TAP-treated group was sig-
nificantly lower than that of the control group.
Fig. 3. Phosphate adsorption rate of TAP. The amounts of
phosphate adsorbed by 1 g of TAP after incubation for 0.5, 1, 2,
3, and 5 h at 37 in 60 mM phosphate solution (NaH2PO4) pH
adjusted to 1.2 (closed circles) or 6.8 (open triangles).
Fig. 4. Optimal pH range for the phosphate adsorption by TAP.
The amounts of phosphate adsorbed by 1 g of TAP at pH rang-
ing from 1.22 to 10.21 were calculated. The results are given as
meansstandard deviation.
Table 3. Average dietary intakes during experimental period
Group Average dietaryintakes (g/31days)
Normal 22.60.35
Control 14.52.14
3% TAP 11.22.03
10% TAP 7.41.05*
3% Sevelamer 12.11.99
3% CaCO3 11.70.84
*Significantly different from control group (P0.05).
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The changes in serum levels of BUN and cre-
atinine are shown in Figure 5. The serum levels of
BUN and creatinine in CRF model rats increased in
a time-dependent manner, while those in the nor-
mal rats were constant. Among the CRF model rats,
BUN levels in those treated with 3% calcium car-
bonate were significantly elevated at 14, 24, and 31
days, while those in TAP-treated rats at 24 days
were significantly decreased in comparison with the
control CRF group (Figure 5a). Serum creatinine
levels showed a similar tendency to those of BUN
(Figure 5b). Serum creatinine levels at 31 days in
rats treated with calcium carbonate were signifi-
cantly higher than those in the control group, while
those in 10% TAP and 3% sevelamer groups were
significantly lower than those in the control group.
The changes in serum phosphate and calcium lev-
els in each group are shown in Figure 6. The serum
phosphate levels of the rats in the control group
increased in a time-dependent manner and reached
17.02.55 mg/dl at 31 days (Figure 6a). With the
exception of 3% sevelamer, all of the test reagents
significantly inhibited the elevation of serum phos-
phate level in CRF model rats. Calcium carbonate
markedly reduced the serum phosphate level to
less than that in the normal group. On the other
Fig. 5. Effects of TAP on serum levels of blood urea nitrogen
(a) and creatinine (b) in rats with adenine- induced renal failure.
The results are shown as meansstandard deviation. *Signifi-
cantly different from control group (P0.05). Normal rats and
control CRF model rats are indicated by open and closed squares,
respectively. Other symbols indicate CRF model rats treated with
CaCO3 (closed triangles), 3% sevelamer (open triangles), 3% TAP
(closed circles), and 10% TAP (open circles), respectively.
Fig. 6. Effects of TAP on serum levels of phosphate (a) and
calcium (b) in rats with adenine- induced renal failure. The re-
sults are shown as meansstandard deviation. *Significantly dif-
ferent from control group (P0.05). Symbols are the same as
in Figure 5.
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hand, serum calcium levels in rats treated with cal-
cium carbonate were significantly higher than those
in the control group (Figure 6b). The serum cal-
cium levels in the control group decreased in a time-
dependent manner, which was indicative of the pro-
gression of renal dysfunction. On the other hand,
the serum calcium levels of TAP- and sevelamer-
treated groups were stable throughout the experi-
ment. The values of calcium by phosphate (CaP)
are plotted in Figure 7. The CaP values in TAP-
treated groups were significantly lower than those
in the control group only at 14 days, while those in
calcium carbonate-treated rats were low similarly
to that of normal rats. On the other hand, the Ca
P values in sevelamer-treated group were similar to
those in controls.
Figure 8 shows the phosphate concentration in
24-h urine. Control CRF model rats showed a simi-
lar urinary phosphate level to the normal group al-
though the dietary intake of CRF model rats was
significantly reduced in comparison with normal rats
(Table 3), reflecting hyperphosphatemia in the con-
trol CRF group. Treatment with TAP (both 3% and
10%) and 3% calcium carbonate significantly reduced
urinary phosphate level. Treatment with 3% seve-
lamer also decreased urinary phosphate level but
the difference was not significant in comparison with
the control group. The results regarding urinary
phosphate level correlated well with those of serum
phosphate level (Figure 6a).
DISCUSSION
In this study, we developed TAP as an inorganic
phosphate adsorbent that has desirable character-
istics for treatment of hyperphosphatemia in CRF
patients. TAP showed rapid phosphate adsorption
in vitro and adsorbed over 65 mg of phosphate per
gram of TAP over a wide pH range under pH7.0,
indicating that TAP is a suitable phosphate-binder
in the human gastrointestinal tract. As ion exchange
through hydroxyl groups was markedly affected by
pH, the wide pH optima of TAP with regard to phos-
phate adsorption is probably due to ion exchange
through stable sulfate groups rather than through
hydroxyl groups, as reported for titanium oxide
monohydrate (23, 24).
We used adenine-induced CRF model rats to
evaluate the capability of TAP to prohibit hyperphos-
phatemia in CRF by comparison with the effects of
other phosphate adsorbents (sevelamer hydrochlo-
ride and calcium carbonate). More than 3-week ad-
ministration of adenine is required to induce the sig-
nificantly higher serum phosphate level than that in
untreated control, and the treatment with adenine
must be continued to maintain CRF condition (22).
However in this model, it has been reported that
19% and 67% of the rats died at 4 and 6 weeks after
administration of adenine, respectively (20). There-
fore, we designed the experiment of 31 days and
started the administration of adenine and test re-
agents simultaneously to avoid the loss of the rats
Fig. 7. Effects of TAP on serum CaP (mg2/dL2) in rats with
adenine- induced renal failure. The results are shown as means
standard deviation. *Significantly different from control group
(P0.05).
Fig. 8. Effects of TAP on urinary phosphate levels in rats with
adenine- induced renal failure. The results are shown as means
standard deviation. *Significantly different from control group
(24day) (P0.05). **Significantly different from control group
(31day) (P0.05).
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due to the prolonged treatment with adenine.
The dietary intakes of adenine-treated groups
were significantly lower than that of untreated nor-
mal group. In adenine-treated groups, the dietary
intake of 10% TAP- treated group was significantly
lower than that in control group (Table 3). This
was probably due to the irritation by strong acidity
of TAP (pH of 10% TAP suspension is 2.2), and the
addition of TAP at 10% concentration into AIN-76
powder diet resulted in the decrease of dietary in-
take in this group.
The administration of adenine induced renal
failure in rats, in which serum BUN and creatinine
levels were elevated in a time-dependent manner
(Figure 5). In calcium carbonate-treated group, se-
rum BUN and creatinine levels were extensively
higher than those in other groups. This reason was
unclear but high calcium intake possibly affects the
renal function synergistically with adenine because
the dietary intake of this group was similar to other
adenine-treated groups.
Serum phosphate levels increased in CRF model
rats in comparison with untreated normal controls.
TAP treatment inhibited the elevation of serum
phosphate level, especially after 24 days of adenine
administration. Serum phosphate levels of all of the
phosphate adsorbent-treated rats were consistently
lower than those in control CRF rats throughout
the experiment. In comparison with calcium carbon-
ate, TAP- and sevelamer-treated groups showed
higher phosphate levels, but both phosphate adsorb-
ents showed sufficient control of serum phosphate
level. This effect was also reflected in 24-h urinary
phosphate level. Both serum and urinary phosphate
levels indicated that TAP adsorbed phosphate in
vivo more effectively than sevelamer hydrochloride.
However, serum levels of BUN and creatinine in
TAP- and severamer-treated groups were lower
than those in control group, indicating that the ad-
ministration of these test reagents inhibit the pro-
gression of renal failure by treatment with adenine.
Therefore, it is possible that the other factors than
phosphate adsorption by TAP and sevelamer in-
volved in the inhibitory effects of these reagents
on serum phosphate levels observed in this study.
In addition, it was difficult to evaluate the effect of
10% TAP on serum phosphate level due to the sig-
nificantly lower dietary intake than those in other
groups. Improvement of administration method (e.g.
coating of TAP particles with cellulose) to reduce
the irritation by TAP is necessary to evaluate the
effect of high-dose TAP on serum phosphate level
in CRF model rats.
Serum calcium level was markedly elevated in
rats treated with calcium carbonate. As hypercal-
cemia induces calcification of blood vessels (25, 26),
the elevated serum BUN and creatinine levels in
calcium carbonate-treated rats may indicate that
hypercalcemia induced kidney malfunction in these
animals. The elevated CaP value is a predictive
risk factor for ectopic calcification (27-29). The Ca
P values in TAP-treated rats were stably lower than
those in control CRF model rats throughout the
experiment, indicating that TAP has a low risk of
inducing ectopic calcification.
In summary, TAP has a high capability for adsorp-
tion of inorganic phosphate over a wide pH range.
TAP also showed this ability in adenine-induced
CRF model rats, where it inhibited the elevation of
serum phosphate level without influencing serum
calcium level. These results indicate that TAP is an
effective phosphate adsorbent working throughout
the intestinal tract. In addition, TAP has none of the
risks associated with aluminum toxicity, hypercal-
cemia, or ectopic calcification. Sevelamer hydrochlo-
ride is a widely used phosphate adsorbent in CRF
patients but constipation is a frequent adverse re-
action due to the volume expansion of this polymer.
On the other hand, TAP does not expand in volume
in the intestinal tract, and is expected to be a phos-
phate adsorbent with less side effects, especially
constipation. TAP is expected to be a good lead
compound from which to develop a novel phosphate
adsorbent for use in CRF patients with lower ad-
verse effects.
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